Kyowa Hakko Kirin Co Ltd (4151.T)
BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab
* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia
* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint
* Trial did not meet its primary endpoint of progression free survival (pfs).
Feb 1 Kyowa Hakko Kirin Co Ltd : * Says it set up KYOWA KIRIN FRONTIER Co., Ltd. * Says the capital is 100 million yen Source text in Japanese:https://goo.gl/pbfRNt Further company coverage: (Beijing Headline News)